肿瘤防治研究2025，Vol.52Issue(9)：787-791,5.DOI:10.3971/j.issn.1000-8578.2025.25.0293
抗体偶联药物治疗胰腺癌的基础研究进展及展望
Basic Research Progress and Prospect of Antibody-Drug Conjugate in Treatment of Pancreatic Cancer
摘要
Abstract
Most patients with pancreatic cancer are already in the locally advanced or metastatic stage at initial diagnosis.While systemic chemotherapy provides clinical benefits for those with mid-to-late-stage pancreatic cancer,its efficacy is often limited by patient tolerance.In response to the dual clinical demands of robust antitumor activity and high targeting specificity,antibody-drug conjugate(ADC)has emerged as a promising solution.By conjugating highly selective monoclonal antibodies with potent cytotoxic small-molecule drugs,ADC achieves precise tumor-targeting while minimizing damage to healthy tissues,which thereby improves treatment tolerance.However,due to the complex pathological features of pancreatic cancer,no ADC has yet been approved for clinical use for this disease.A comprehensive evaluation of factors including ADC-specific targets,payload selection,antibody-drug linkage strategies,drug delivery mechanisms,tissue distribution variability,and tumor heterogeneity will be crucial to advancing the clinical translation of ADC for pancreatic cancer treatment.关键词
胰腺癌/抗体偶联药物/基础研究Key words
Pancreatic cancer/Antibody-drug conjugate/Basic research分类
医药卫生引用本文复制引用
焦巨英,周蕾,林博,曾静怡,徐蔚杰..抗体偶联药物治疗胰腺癌的基础研究进展及展望[J].肿瘤防治研究,2025,52(9):787-791,5.基金项目
National Natural Science Foundation of China(No.82405086) 国家自然科学基金(82405086) （No.82405086）
